Why the study?
SCORE2 was developed to predict ASCVD in Europe, but whether these models could be used outside of Europe was unknown.
Does the SCORE2 model accurately predict 5-year ASCVD risk in a Canadian primary care cohort?
Population
57 409 individuals aged 40-69 and 9885 individuals aged 70-89 in Ontario, Canada
Comparison
Uncalibrated vs low-risk region recalibrated SCORE2 models
Design
Primary care cohort validation study
Authors
Loading...
May overestimate risk in Canadian women with recalibrated SCORE2-YP; leaves open need for local validation before adoption.
Does the SCORE2 model accurately predict 5-year ASCVD risk in a Canadian primary care cohort?
The performance of the European SCORE2 model for predicting ASCVD risk in a Canadian cohort varied significantly by age group and calibration method, highlighting the need for regional validation before clinical implementation.
Sud et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: